Evidence for a Direct Growth-stimulating Effect of Estradiol on Human MCF-7 Cells in Vivo

Robert A. Huseby, Terry M. Maloney, and Charles M. McGrath

Department of Tumor Biology, Michigan Cancer Foundation, Detroit, Michigan 48201

ABSTRACT

The MCF-7 continuous line of human breast cancer cells requires that athymic nude mice receive supplemental estrogen so that inocula can produce progressively growing tumors. Although these cells contain a typical estrogen receptor complex, the lack of consistent growth stimulation induced by estrogens added to in vitro culture systems has raised the question as to whether this class of hormones acts directly upon the cells or induces a second message produced in other tissues. The present experiments were designed to test the effect of estradiol on the growth of these cells in vivo by exposing them directly to the hormone prior to its absorption into the hepatic portal circulation and subsequent metabolic inactivation. Tumor fragments that were placed next to an estradiol-containing pellet in the spleen grew to produce grossly evident tumor masses, whereas those in the subcutis of the same animals did not, although some minute residua did remain. In the splenic tumors, the mitotic index of the MCF-7 cells immediately adjacent to the estrogen pellets was 2.4 times that of cells on the other side of the same tumor and 3.5 times that of those in the minute s.c. residua. We interpret these data as indicating that in vivo estradiol is acting directly upon the MCF-7 cells to increase their rate of proliferation rather than to initiate the production of a second message to be released into the circulation.

Additionally, it was found that s.c. tumors that were decreasing in volume subsequent to withdrawal of systemic estrogen still contained dividing neoplastic cells but with a lower frequency than that seen in progressively growing tumors stimulated with estradiol. This finding indicates that MCF-7 cells can proliferate in vivo in the absence of a substantial amount of estrogen but only at a rate insufficient to sustain progressive tumor growth.

INTRODUCTION

It has been found routinely that the continuous culture line of human breast cancer cells, MCF-7, requires supplemental estrogen administration in order to sustain progressive growth in athymic nude mice (17, 20). The effect of adding estrogen to the culture medium on the rate of proliferation of these cells in vitro has varied from laboratory to laboratory. Lippman et al. (13) first reported a significant stimulatory effect that has been noted by few others (1, 14). Most investigators have failed in their attempts to reproduce such an effect (11, 16, 18), and this has led to the suggestion that the in vivo stimulatory action of estrogen is indirect (16, 18), possibly mediated through the elaboration in distant tissues of a second messenger (9, 19).

In the present study, we attempt to demonstrate that the in vivo growth stimulatory effect of estradiol on MCF-7 cells in nude mice is, in fact, an action exerted by the hormone directly upon the neoplastic cells. The design of the experiments, used successfully in the mouse Leydig cell tumor model (6, 8), depends on the original experiments of Biskind and Biskind (2), who demonstrated the capacity of the liver to inactivate the estrogenic effects of biologically active steroidal estrogens introduced into the hepatic portal circulation. Thus, estrogen sources placed in the spleen should produce a localized sphere of active hormone due to diffusion into the surrounding extracellular fluid yet fail to produce a systemic stimulation because the venous effluent would be cleared of biologically active hormone during its first passage through the liver. The effects of estrogen withdrawal on growing tumor masses in nude mice are also investigated in order to buttress some of the observations indicating that estradiol does exert its proliferation-promoting effects directly upon the MCF-7 cells.

MATERIALS AND METHODS

The animals used were from the colony of congenitally athymic nu/nu mice on a BALB/c background maintained at the Michigan Cancer Foundation. Castrated males, 6 to 8 weeks old, were used throughout in order to avoid the development of pyometria commonly associated with the chronic administration of estrogen to females of this genetic constitution. They were housed in laminar-flow units in a room that had a 12-hr light-dark photoperiodity and was humidified and temperature controlled. Cages, bedding, food, and water were sterilized, and the latter 2 were available at all times. Estrogen was administered as a 7.5-mg fused 17β-estradiol:cholesterol (15:85 w/w) pellet ¼ inch in diameter (22). In previous experiments (6, 8), normal and neoplastic testicular tissue has been placed subcapsularly in the spleen using a 17-gauge spinal needle as a trocar. When this procedure was done with small bits of growing MCF-7 tumor and the explants were placed into the subcutis of estrogenized nu/nu mice, only 1 of 20 grafts produced a growing tumor mass. Therefore, for the experiments reported here, tumor fragments, usually about 1 mm in diameter, were positioned appropriately using a fine thumb forceps. These fragments were prepared from excised tumors growing as second- or third-generation transfers in estrogenized nude mice by careful mincing in sterile minimal essential medium using crossed scalpels blades.

In brief, the surgical procedure consisted of a basal anesthetic with Nembutal, maintaining relaxation with open-drop ether. A 1-cm midline skin incision was made just caudal to the xiphoid, the abdominal cavity was entered by incising along the linea alba, and the caudal half of the spleen was delivered through the incision. The tip of the spleen was grasped with a blunt curved-thumb forceps, and a small incision was made through the pancreatic surface of the capsule 4 to 6 mm from the tip. A small pocket was then produced by blunt dissection between the capsule and the splenic pulp. When desired, a hormone pellet was inserted into the pocket followed by the placement of a tumor fragment; otherwise, only a fragment of tumor was placed in the pocket. No attempt was made to suture close the incision in the splenic capsule. The spleen was dropped back into the abdomen, and the incision in the abdominal wall was sutured with 5-0 absorbable gut. By blunt dissection through the same skin incision, a tumor fragment of similar size was placed in the subcutis of the right thorax, and when systemic estrogenization was
tumors in systemically estrogenized animals measured from 7 to 10 mm
necropsied, most between 75 and 105 days postsurgery, when the s.c.
desired, an estradiol:cholesterol pellet was similarly placed in the left
masses were measured in 2 perpendicular diameters. All animals were
An animals were observed at weekly intervals, and all s.c. tumor
for residua. Tissues were fixed in 10 ml formalin, 45 ml 80% methanol,
found between those tumors weighing less than 100 and those exceed
this variation was quite large, the S.E. of 26 or more tumors would only
tumors were removed and weighed. The mean of the calculated volumes
where di was the larger diameter and d2 the smaller, since the lesser of
paraffin, sectioned at 5 μm, and stained with hematoxylin:eosin. M12
tumor masses were found in the abdominal cavity outside the
nu/nu mice were measured, the animals sacrificed, and the
RESULTS
Animals Bearing s.c. 17β-Estradiol Pellets. As recorded in
Volume = d1 x d2 x d2 x 0.5236
where d1 was the larger diameter and d2 the smaller, since the lesser of
where di was the larger diameter and d2 the smaller, since the lesser of
determinations were made under oil immersion evaluating 20 to 25
tissues were fixed in 10 ml formalin, 45 ml 80% methanol, 45 ml 80% ethanol, and 5 ml glacial acetic acid, dehydrated, mounted in
_histologically, the tumor masses next to the intrasplenic estradici pellets were similar to those growing progressively in the
intrapancreatic areas of the spleen and pancreas, i.e., no fragments or free cells
regions where the s.c. grafts had been placed were searched
animals of 5 separate experiments. However, in 8 of 15 mice in
same animal exceeded 10 mm in diameter, was entirely outside the
Animals with 17β-Estradiol Pellets Placed in the Spleen. At
necropsy, no instances were encountered in which vascular
Histologically, the tumor masses next to the intrasplenic estradiol pellets were similar to those growing progressively in the
seemingly insignificant lower than that of growing s.c. implants. From
the location of the tumors, it was obvious that a consider-
progressively growing tumors in estrogenized nu/nu mice were measured, the animals sacrificed, and the
were recovered from the splenic-
were always being implanted (4,10).
At necropsy, tumor masses were recovered from the splenic-
Survival of Residual Tumor Cells. Histologically, no evidence of
necropsy, the abdominal contents were scrutinized under × 7 to ascertain if adhesions had formed between the spleen and the peritoneum and to look for tumor deposits.
Similarly, the areas where the s.c. grafts had been placed were searched
areas where the s.c. grafts had been placed were searched
 were found, and in other animals, sections of intrapancreatic
tumor masses occasionally revealed emboli of tumor cells within
lymphatic channels at a distance from the main tumor masses.

Animals Bearing nu/nu Mice Xenografted with Intrapancreatic Tumor Cells. As recorded in

Histologically, the tumor masses next to the intrasplenic estradiol pellets were similar to those growing progressively in the
subcutaneous areas of the spleen and pancreas, i.e., no fragments or free cells of the mice had intraabdominal tumor masses that were evident grossly. This incidence was significantly less (p < 0.02) than that observed with the s.c. implantation of fragments of similar size into systemically estrogenized recipients and most probably resulted from failure of the grafts to be retained in close approximation to the estrogen source for a sufficient period after the conclusion of surgery. All 10 of the tumors observed were in close approximation to an estradiol capsule (Figs. 1 and 3). All but one were between 3 and 7 mm in largest diameter and extended beyond the confines of the spleen capsule. The tumor in a single animal exceeded 10 mm in diameter, was entirely outside the
spleen and the hormone pellet, which was in contact with the
surface of the tumor, and was separated from the free peritoneal
developed progressive tumors in the subcutaneous areas of the spleen and pancreas, i.e., no fragments or free cells of the mice had intraabdominal tumor masses that were evident grossly. This incidence was significantly less (p < 0.02) than that observed with the s.c. implantation of fragments of similar size into systemically estrogenized recipients and most probably resulted from failure of the grafts to be retained in close approximation to the estrogen source for a sufficient period after the conclusion of surgery. All 10 of the tumors observed were in close approximation to an estradiol capsule (Figs. 1 and 3). All but one were between 3 and 7 mm in largest diameter and extended beyond the confines of the spleen capsule. The tumor in a single animal exceeded 10 mm in diameter, was entirely outside the
spleen and the hormone pellet, which was in contact with the
surface of the tumor, and was separated from the free peritoneal

JUNE 1984 2655

2 The abbreviation used is: M1, mitotic index.
large enough to present an adequate number of cells in a single cross-section to obtain a reasonable evaluation of the MI. An equal number of progressively growing tumors was selected from systemically estrogenized hosts in the same experiments for comparison, and the data are presented in Table 2. It is obvious that the percentage of cells undergoing mitosis was significantly less in the small residuals than in the tumors that were growing progressively in systemically estrogenized animals. In both situations, cells with pyknotic nuclei and bare nuclear fragments were numerous, indicating a high rate of cell death. The centers of the growing tumors were routinely composed of connective tissue containing but few recognizable tumor cells.

These data suggested a method of analysis that could be of value in establishing more firmly the gross tumor observations indicating that estradiol exerts its growth-promoting effects by increasing directly the rate of proliferation of MCF-7 cells. According to the thesis upon which these experiments were designed, the effective stimulation from the intrasplenic estradiol pellets depended on diffusion of the estrogen through the extraacellular fluid in the immediate vicinity prior to its entry into the hepatic portal circulation. One would not expect this sphere of diffusion to be very large (Ref. 6; Table 3) so that in a tumor >3 mm in diameter those neoplastic cells near the pellet should reside in a milieu of higher estrogen concentration than would those at the opposite pole of the tumor mass. Three animals in which the hormone pellet remained within the spleen had both a small residual s.c. nodule and a considerably larger tumor mass next to the estradiol pellet and 5 on the opposite side.

Comparison of the MI of progressively enlarging s.c. MCF-7 grafts in systemically estrogenized athymic nude mice and s.c. tumor residua in mice bearing i.s. estradiol:cholesterol pellets

<table>
<thead>
<tr>
<th>Experiment</th>
<th>Pellet location</th>
<th>No. of tumors</th>
<th>No. of cells counted</th>
<th>MI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>C107</td>
<td>s.c.</td>
<td>4</td>
<td>4736</td>
<td>0.0150</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>i.s.</td>
<td>4</td>
<td>7406</td>
<td>0.0046</td>
<td></td>
</tr>
<tr>
<td>C96</td>
<td>s.c.</td>
<td>1</td>
<td>1606</td>
<td>0.0199</td>
<td>0.021</td>
</tr>
<tr>
<td></td>
<td>i.s.</td>
<td>1</td>
<td>720</td>
<td>0.0069</td>
<td></td>
</tr>
<tr>
<td>Combined</td>
<td>s.c.</td>
<td>5</td>
<td>6402</td>
<td>0.0162</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>i.s.</td>
<td>5</td>
<td>8126</td>
<td>0.0048</td>
<td></td>
</tr>
</tbody>
</table>

* I.s., intrasplenic.

Comparison of the MI of MCF-7 tumor cells next to an i.s. estradiol:cholesterol pellet with those in the same tumor mass opposite the pellet and with those in the s.c. residual of the same animal

<table>
<thead>
<tr>
<th>Animal</th>
<th>Location of tumor cells</th>
<th>No. of cells counted</th>
<th>MI</th>
<th>p</th>
<th>difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>C96-5</td>
<td>s.c.</td>
<td>720</td>
<td>0.0069</td>
<td>0.0102</td>
<td></td>
</tr>
<tr>
<td></td>
<td>i.s.</td>
<td>1203</td>
<td>0.0224</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Next to pellet</td>
<td>1270</td>
<td>0.0094</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i.s.</td>
<td>1992</td>
<td>0.0181</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Opposite pellet</td>
<td>2419</td>
<td>0.0087</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C107-7</td>
<td>s.c.</td>
<td>2080</td>
<td>0.0082</td>
<td>0.0045</td>
<td></td>
</tr>
<tr>
<td></td>
<td>i.s.</td>
<td>1992</td>
<td>0.0181</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Next to pellet</td>
<td>2419</td>
<td>0.0087</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i.s.</td>
<td>1448</td>
<td>0.0069</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C107-6</td>
<td>s.c.</td>
<td>2132</td>
<td>0.0028</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>i.s.</td>
<td>959</td>
<td>0.0219</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Next to pellet</td>
<td>1448</td>
<td>0.0069</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>i.s.</td>
<td>4154</td>
<td>0.0202</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Opposite pellet</td>
<td>5137</td>
<td>0.0084</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Combined

* I.s., intrasplenic.

*p = 0.107, as compared to combined s.c.

compared to that seen in the s.c. residua was not statistically significant with the number of cells available for comparison. These data would indicate that the major growth of the intraabdominal tumors was occurring in an area close to the estradiol-containing pellets as a direct result of the high concentration of hormone in this region.
Mitotic Activity in Regressing Tumors. The presence of dividing cells in the residual s.c. nodules of some of the mice bearing pelleted estradiol in the hepatic portal drainage system raised the question as to whether these foci of MCF-7 cells had been maintained as a result of incomplete inactivation of the estrogen in its first passage through the liver or if a low level of proliferation can proceed in the absence of significant amounts of circulating estrogen. To test this, 16 estrogenized castrated male mice were given bilateral implants in the s.c. tissues of the thorax with MCF-7 fragments of slightly larger size, 1 to 2 mm in diameter, from 2 separate donor tumors. Thirty-one of these grafts resulted in progressively growing tumors that were readily measurable 26 days later. Growth was allowed to proceed for another 21 days, at which time the estrogen pellets were removed. As recorded in Chart 1, the size of the tumors decreased slowly over the next 77 days, at which time the calculated mean tumor volume was 41% of that at the time of pellet removal ($p = 0.0005$). Representative tumors were excised for histological evaluation. Microscopic examination revealed a marked increase in fibrous connective tissue relative to the number of neoplastic epithelial cells present within each tumor mass. The fibrocytes did not appear to be actively proliferating at this time, so that the stroma consisted primarily of dense strands of adult collagen. Additionally, in widely dispersed foci, collections of lymphocytes were evident, but these were not surrounding the clumps of viable-appearing tumor cells. The neoplastic cells themselves were smaller, with considerably less cytoplasm than were those in progressively growing tumors under the influence of estrogen stimulation. Mitotic activity was still evident in this neoplastic epithelium, and as shown in Table 4, the MI in 6 tumors exhibiting different degrees of regression was similar to that found in the nongrowing s.c. residua in animals carrying an intrasplenic estradiol pellet. Ten tumors were observed for an additional 18 weeks, i.e., a total period of 7 months in the absence of estradiol stimulation, without further diminution in size or instances of regrowth.

DISCUSSION

In these experiments, tumor growth was sustained only when MCF-7 cells were in a milieu containing estrogenically active steroid. It is difficult to formulate a scenario in which the estradiol was causing the production by host cells of some active substance that then entered the circulation to stimulate proliferation of MCF-7 cells. It is unlikely that hepatic production of such a factor (12) is involved in this growth process. As is evident in Fig. 3, very little tissue separated the intrasplenic estradiol:cholesterol pellets from the most actively growing portion of the adjoining tumor masses. This thin tissue membrane was composed of a row of large macrophagic cells supported by a very thin layer of fibrous connective tissue. It seems logical to conclude, therefore, that the growth-promoting effects of the estrogen resulted from an action of estradiol directly on the MCF-7 cells mediated through the estrogen receptor system they contain (3, 5), although the possible importance of the stroma in this response is not to be overlooked. The greater MI found in tumor tissues residing in a milieu of higher estradiol concentrations indicates that the resultant increase in tumor mass was effected primarily through an increased rate of tumor cell proliferation, although some diminution in the microscopically apparent high rate of tumor cell death cannot be ruled out. That estrogens stimulate direct growth of MCF-7 cells in vivo does not alter the fact that the growth of cells in the presence of estrogen can be enhanced by other hormones, e.g., those of pancreatic and hypophysial origin (15, 16, 21). It is well to point out, however, that administered estrogen has been shown to produce a rate of growth of this tumor implanted in hypophysectomized athymic mice quite comparable to that seen in ovariec- tomized mice receiving the same amount of estradiol (16).

In the experiments reported here, both a decrease in and stasis of tumor size occurred in the face of active tumor cell proliferation. This is in contrast to the situation recently detailed in estrogen-induced Leydig cell tumors in mice (7). In that model, regression of estrogen-dependent tumors following hormone deprivation was associated with a disappearance of mitotic activity and led to a state of true dormancy in which nonproliferating neoplastic cells remained at the tumor site to be reactivated quickly when estrogen treatment was reinstituted. Which situation pertains in cases of breast cancer in patients where tumor regressions have been produced in response to hormone withdrawal has not been established. The sustained regression of progressively enlarging MCF-7 tumors following removal of the estrogen source recorded here was not observed in an earlier report from another laboratory (17). This could well represent variations in the cell population of MCF-7 cells maintained in different laboratories as suggested by the variance reported in their in vitro response to added estradiol.

REFERENCES

2. Biskind, M. S., and Biskind, G. R. Development of tumors in rat ovary after

---

Table 4

<table>
<thead>
<tr>
<th>Tumor</th>
<th>% of decrease in calculated volume</th>
<th>No. of cells counted</th>
<th>MI</th>
</tr>
</thead>
<tbody>
<tr>
<td>C117-8, Left</td>
<td>0</td>
<td>2890</td>
<td>0.0080</td>
</tr>
<tr>
<td>C118-5, Left</td>
<td>16</td>
<td>1314</td>
<td>0.0061</td>
</tr>
<tr>
<td>C118-2, Left</td>
<td>54</td>
<td>1533</td>
<td>0.0033</td>
</tr>
<tr>
<td>C117-9, Left</td>
<td>56</td>
<td>1172</td>
<td>0.0051</td>
</tr>
<tr>
<td>C117-14, Right</td>
<td>59</td>
<td>1432</td>
<td>0.0042</td>
</tr>
<tr>
<td>C117-12, Left</td>
<td>82</td>
<td>1421</td>
<td>0.0035</td>
</tr>
</tbody>
</table>

---

Chart 1. Growth of 31 MCF-7 tumor grafts under the influence of estradiol stimulation for 67 days and their regression over 77 days after estrogen withdrawal. Estradiol pellets removed.
R. A. Huseby et al.


Fig. 1. Section through an intrasplenic estradiol:cholesterol pellet (EP) with actively proliferating MCF-7 tumor (Tu), at one end and extending through the splenic (Sp) capsule and protruding into pancreatic tissues (Pa), x 30.

Fig. 2. A s.c. MCF-7 residuum in the same animal, C107-7, illustrated in Fig. 1. This was the largest of 8 s.c. residua found in animals with an intrasplenic estradiol:cholesterol pellet. x 30.

Fig. 3. Higher magnification of tumor illustrated in Fig. 1. The clear area to the right is space occupied by the estradiol:cholesterol pellet (EP) before being dissolved during histological preparation. Note the rim of macrophagic cells (Ma) supported by a thin layer of fibrinous connective tissue separating the pellet from actively proliferating MCF-7 cells. Mi, mitotic figure, x 500.

Fig. 4. Higher magnification of residual tumor shown in Fig. 2. Note relative larger amounts of connective tissue stroma and lesser amounts of cytoplasm about the tumor nuclei as compared to those in Fig. 3. A mitotic figure (Mi) is shown quite clearly. x 500.
Evidence for a Direct Growth-stimulating Effect of Estradiol on Human MCF-7 Cells \textit{in Vivo}

Robert A. Huseby, Terry M. Maloney and Charles M. McGrath


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/44/6/2654

\begin{tabular}{|l|l|}
\hline
\textbf{E-mail alerts} & Sign up to receive free email-alerts related to this article or journal. \\
\hline
\textbf{Reprints and Subscriptions} & To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. \\
\hline
\textbf{Permissions} & To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. \\
\hline
\end{tabular}